Enzalutamide has modest clinical activity in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel and abiraterone acetate, according to the largest study of this therapeutic approach to date. Of 69 patients, 21% experienced a maximum PSA decline of ≥50%, and enzalutamide was generally well tolerated in this cohort. PSA response to docetaxel and abiraterone did not predict PSA response to enzalutamide.
References
Badrising, S. et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 10.1002/cncr.28518
Rights and permissions
About this article
Cite this article
Enzalutamide effective as third-line therapy. Nat Rev Urol 11, 67 (2014). https://doi.org/10.1038/nrurol.2014.4
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.4